210 related articles for article (PubMed ID: 26562541)
1. Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
Dixit PP; Dixit PP; Thore SN
Eur J Med Chem; 2016 Jan; 107():38-47. PubMed ID: 26562541
[TBL] [Abstract][Full Text] [Related]
2. Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
Pieroni M; Machado D; Azzali E; Santos Costa S; Couto I; Costantino G; Viveiros M
J Med Chem; 2015 Aug; 58(15):5842-53. PubMed ID: 26197353
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore.
Salunke SB; Azad AK; Kapuriya NP; Balada-Llasat JM; Pancholi P; Schlesinger LS; Chen CS
Bioorg Med Chem; 2015 May; 23(9):1935-43. PubMed ID: 25818768
[TBL] [Abstract][Full Text] [Related]
4. Sequential synthesis of amino-1,4-naphthoquinone-appended triazoles and triazole-chromene hybrids and their antimycobacterial evaluation.
Devi Bala B; Muthusaravanan S; Choon TS; Ashraf Ali M; Perumal S
Eur J Med Chem; 2014 Oct; 85():737-46. PubMed ID: 25129868
[TBL] [Abstract][Full Text] [Related]
5. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections.
Amaral L; Viveiros M
Int J Antimicrob Agents; 2012 May; 39(5):376-80. PubMed ID: 22445204
[TBL] [Abstract][Full Text] [Related]
6. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
[TBL] [Abstract][Full Text] [Related]
7. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.
Kumar M; Singh K; Naran K; Hamzabegovic F; Hoft DF; Warner DF; Ruminski P; Abate G; Chibale K
ACS Infect Dis; 2016 Oct; 2(10):714-725. PubMed ID: 27737555
[TBL] [Abstract][Full Text] [Related]
10. L-proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines.
Indumathi S; Perumal S; Banerjee D; Yogeeswari P; Sriram D
Eur J Med Chem; 2009 Dec; 44(12):4978-84. PubMed ID: 19781824
[TBL] [Abstract][Full Text] [Related]
11. Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.
Addla D; Jallapally A; Gurram D; Yogeeswari P; Sriram D; Kantevari S
Bioorg Med Chem Lett; 2014 Jan; 24(1):233-6. PubMed ID: 24314670
[TBL] [Abstract][Full Text] [Related]
12. Novel 1,4-substituted-1,2,3-triazoles as antitubercular agents.
Altimari JM; Hockey SC; Boshoff HI; Sajid A; Henderson LC
ChemMedChem; 2015 May; 10(5):787-91. PubMed ID: 25788466
[TBL] [Abstract][Full Text] [Related]
13. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
[TBL] [Abstract][Full Text] [Related]
14. Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis.
Kumar M; Singh K; Ngwane AH; Hamzabegovic F; Abate G; Baker B; Wiid I; Hoft DF; Ruminski P; Chibale K
Bioorg Med Chem; 2018 Feb; 26(4):833-844. PubMed ID: 29373270
[TBL] [Abstract][Full Text] [Related]
15. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and in vitro anti-mycobacterial evaluation of gatifloxacin-1H-1,2,3-triazole-isatin hybrids.
Xu Z; Zhang S; Song X; Qiang M; Lv Z
Bioorg Med Chem Lett; 2017 Aug; 27(16):3643-3646. PubMed ID: 28720502
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in-vitro antimycobacterial evaluation of 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro- 8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids.
Senthilkumar P; Dinakaran M; Chandraseakaran Y; Yogeeswari P; Sriram D
Arch Pharm (Weinheim); 2009 Feb; 342(2):100-12. PubMed ID: 19137533
[TBL] [Abstract][Full Text] [Related]
18. 4H-1,3-Benzothiazin-4-one a Promising Class Against MDR/XDR-TB.
de Souza MVN; Nogueira TCM
Curr Top Med Chem; 2019; 19(8):567-578. PubMed ID: 30834835
[TBL] [Abstract][Full Text] [Related]
19. Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of Mycobacterium tuberculosis.
Yempala T; Sridevi JP; Yogeeswari P; Sriram D; Kantevari S
Eur J Med Chem; 2014 Jan; 71():160-7. PubMed ID: 24292337
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms by which thioridazine in combination with antibiotics cures extensively drug-resistant infections of pulmonary tuberculosis.
Amaral L; Molnar J
In Vivo; 2014; 28(2):267-71. PubMed ID: 24632985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
